Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 98 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2015

Summary 

Global Markets Direct's, 'Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Otsuka Holdings Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Otsuka Holdings Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Otsuka Holdings Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Otsuka Holdings Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Otsuka Holdings Co., Ltd.'s pipeline products

Reason To Buy 

- Evaluate Otsuka Holdings Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Otsuka Holdings Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Otsuka Holdings Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Otsuka Holdings Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Otsuka Holdings Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Otsuka Holdings Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Otsuka Holdings Co., Ltd. Snapshot 7
Otsuka Holdings Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Otsuka Holdings Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Otsuka Holdings Co., Ltd. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Otsuka Holdings Co., Ltd. - Pipeline Products Glance 17
Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Otsuka Holdings Co., Ltd. - Drug Profiles 21
(tipiracil hydrochloride + trifluridine) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
aripiprazole 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
brexpiprazole 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
tolvaptan 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
trabectedin 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
(aripiprazole + sertraline) 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(carteolol hydrochloride + latanoprost) 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
delamanid 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
nabiximols 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rebamipide 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(dextromethorphan hydrobromide + quinidine sulfate) 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AVP-786 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
OCV-101 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
OCV-501 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
OPA-15406 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
probucol 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
tetomilast 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
OPA-6566 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
OPB-111001 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
OPB-31121 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LPC-01 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
OCVC-02 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
OPB-111077 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
OPB-51602 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
OPC-108459 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
OPS-2071 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Otsuka Holdings Co., Ltd. - Pipeline Analysis 61
Otsuka Holdings Co., Ltd. - Pipeline Products by Target 61
Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration 63
Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type 64
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action 65
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates 67
Otsuka Holdings Co., Ltd. - Dormant Projects 88
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products 89
Discontinued Pipeline Product Profiles 89
(tipiracil hydrochloride + trifluridine) 89
AVP-13358 89
AZD-2479 89
rebamipide 89
Otsuka Holdings Co., Ltd. - Company Statement 90
Otsuka Holdings Co., Ltd. - Locations And Subsidiaries 91
Head Office 91
Other Locations & Subsidiaries 91
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98

List of Tables

Otsuka Holdings Co., Ltd., Key Information 7
Otsuka Holdings Co., Ltd., Key Facts 7
Otsuka Holdings Co., Ltd. - Pipeline by Indication, 2015 9
Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2015 12
Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2015 13
Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015 14
Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2015 15
Otsuka Holdings Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 16
Otsuka Holdings Co., Ltd. - Pre-Registration, 2015 17
Otsuka Holdings Co., Ltd. - Phase III, 2015 18
Otsuka Holdings Co., Ltd. - Phase II, 2015 19
Otsuka Holdings Co., Ltd. - Phase I, 2015 20
Otsuka Holdings Co., Ltd. - Pipeline by Target, 2015 62
Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2015 63
Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2015 64
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 66
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates, 2015 67
Otsuka Holdings Co., Ltd. - Dormant Developmental Projects,2015 88
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products, 2015 89
Otsuka Holdings Co., Ltd., Other Locations 91
Otsuka Holdings Co., Ltd., Subsidiaries 91